Objective: After complete resection of carcinomas of the head and neck, including carcinoma of the cervical esophagus, the pattern of first failure is more often locoregional than distant metastasis. We retrospectively evaluated the safety and efficacy of the combination of postoperative radiation and concurrent chemotherapy with low-dose cisplatin for high-risk squamous cell carcinoma of the cervical esophagus. Methods: From 2005 through 2008, 34 patients with previously untreated squamous cell carcinoma of the cervical esophagus underwent cervical esophagectomy with or without laryngectomy. Of these 34 patients, 11 with disease-positive lymph nodes in the upper mediastinum (M1 lymph/Stage IV) confirmed by pathologic examination were enrolled. Patients received radiotherapy (66 Gy in 33 fractions) and concurrent low-dose cisplatin. Results: Nine patients completed the planned radiotherapy and two or more courses of chemotherapy. Grade 3 toxicities during chemoradiotherapy were leukopenia (36% of patients), neutropenia (18%) and mucositis (9%). At a median follow-up time of 39.5 months, the overall 1-and 3-year survival rates were 91 and 71%, respectively. Conclusions: The combination of post-operative radiation and concurrent chemotherapy with low-dose cisplatin is well tolerated and has the potential to improve the rates of locoregional control and overall survival in patients with high-risk advanced squamous cell carcinoma of the esophagus.
INTRODUCTION
Locally advanced head and neck cancer is optimally treated with multimodal approach, involving resection followed by radiotherapy and concurrent chemotherapy (1) . Carcinoma of the cervical esophagus has a poor prognosis, with reported 3-and 5-year survival rates ranging from 18 to 35.4% and from 12 to 33%, respectively (2) . We have previously reported on the prognosis, patterns of first failure and significant clinicopathologic factors affecting survival in cases of squamous cell carcinoma of the cervical esophagus (2) . In particular, the 3-year survival rate was 0% in patients with metastasis to mediastinal lymph nodes (M1 lymph/Stage IV). We have maintained that multimodal treatment, such as post-operative radiotherapy with concurrent chemotherapy, is essential for the treatment of cervical esophageal carcinoma (2) . On the basis of the results of our previous study, we performed a pilot study and retrospectively assessed the toxic effects and efficacy of the combination of post-operative radiotherapy and concurrent chemotherapy with low-dose cisplatin in selected patients who had squamous cell carcinoma of the cervical esophagus with metastasis to the upper mediastinal lymph nodes (M1 lymph/Stage IV), a factor indicating an extremely poor prognosis.
PATIENTS AND METHODS

PATIENTS POPULATION AND ELIGIBILITY
From January 2005 through December 2008, 34 patients with previously untreated carcinoma of the cervical esophagus underwent surgical resection at the National Cancer Center Hospital East. The clinical and pathologic characteristics of the 34 patients are shown in Table 1 . Pre-operative and post-operative staging was based on the 1997 International Union Against Cancer TNM classification. Cases with metastasis to the mediastinal lymph nodes were classified as M1-lymph disease.
All patients with metastasis to the upper mediastinal lymph nodes (M1 lymph/Stage IV) defined as complete removal of all macroscopic tumor masses were eligible for the study if they met all of the following criteria: histologically confirmed diagnosis of squamous cell carcinoma; age of 18 years or older and 75 years or younger; performance status of 0 or 1 according to the Eastern Cooperative Oncology Group scale; adequate bone marrow, hepatic and renal function; no previous chemotherapy or radiotherapy; and written informed consent provided before recruitment.
PRE-TREATMENT EVALUATION
Pre-treatment evaluations in all patients included physical examination, barium-swallow examination, endoscopy with biopsy, ultrasonography of the neck and computed tomography of the neck and chest.
STUDY TREATMENT
The protocol required that radiotherapy be performed as soon as satisfactory healing had occurred after surgery. The protocol also called for radiotherapy to start within 8 weeks after surgery.
The treatment consisted of two or three cycles of cisplatin at a dose of 20 mg/m 2 of body surface area on days 1 -4, 22 -25 and 43-46, repeated every 3 weeks, with concurrent radiotherapy to a total dose of 66 Gy in 33 fractions over 6 weeks.
Because gross tumors were already resected, gross tumor volume was not defined in the case of adjuvant radiotherapy. Clinical target volume (CTV) was defined as the total volume of the surgical bed of the primary tumor plus volumes and metastatic lymph nodes considered at risk of containing microscopic disease. The CTV was further categorized into two volumes: the CTV boost (CTVb), which included the surgical bed of the primary tumor and metastatic lymph nodes, and the CTV subclinical (CTVs), which included the CTVb plus regional lymph nodes (cervical, supraclavicular and superior mediastinum lymph node areas) (Fig. 1) . The upper cervical lymph node area (level II) was excluded from the irradiation field if no lymph node metastasis was found in this area. From four to eight beams were applied from various angles to the CTVs to a total dose of up to 46 Gy. A booster dose of 20 Gy was given to the CTVb using multiple fields to shield the spinal cord for a total dose of 66 Gy. TOXICITY ASSESSMENT AND DOSE MODIFICATION Toxicity assessments, including complete blood cell counts and serum chemistry profiles, were performed weekly during chemoradiotherapy and every 3 weeks during the protocol study. Toxicity assessments for all patients were performed with the National Cancer Institute Common Toxicity Criteria (version 3.0). The dose was reduced by 20% if any toxicity reached Grade 3.
FOLLOW-UP
All patients were regularly followed up with routine physical and laboratory examinations at our hospital. Computed tomography of the neck and chest was performed annually to detect possible recurrent disease. The median follow-up period for all patients was 39.5 months (range, 12-64 months).
STATISTICAL ANALYSIS
Survival time was measured from the date of surgery until death or the most recent follow-up examination. Length of survival was determined with the Kaplan -Meier method, and the log-rank test was used for comparisons. All analyses were performed with the SPSS statistical software package (version 17.0.2; SPSS, Inc., Chicago, IL, USA).
RESULTS
PATIENT CHARACTERISTICS
Pathologic examination showed lymph node involvement in the upper mediastinum in 13 patients ( Table 1) . Eleven of 13 patients were enrolled to receive post-operative radiotherapy with concurrent chemotherapy, but 2 of the 13 patients refused post-operative adjuvant treatment. The baseline characteristics of patients enrolled in this protocol are shown in Table 2 . The median age was 58 years (age range, 40 -70 years), and eight patients were men and three were women. More than 70% of tumors were clinically T3 or T4. Seventy-three percent of tumors had metastasized to lymph nodes before operation. Pathologic characteristics of selected patients with metastases to the upper mediastinal lymph node are listed in Table 3 . Seventy-two percent of tumors were T3 or T4, and all patients had regional lymph node involvement. Complete resection (R0) was achieved in 82% of the patients.
COMPLIANCE WITH TREATMENT
Nine patients (82%) completed post-operative radiotherapy with two or more of concurrent chemotherapy with cisplatin.
One patient who had received 66 Gy of radiotherapy stopped chemotherapy after receiving one cycle. Another patient stopped radiotherapy after receiving a radiation dose of 54 Gy. Toxicity was assessed in all 11 patients. With a median follow-up period of 39.5 months (range, 16 -64 months), the median survival time was 33 months. The 1-and 3-year overall survival rates were 90 and 67%, respectively (Fig. 2) . Tumors recurred in four patients (36%). The pattern of recurrence was more often distant metastasis (75%) than locoregional spread (0%).
TOXICITY
All toxicities are listed in Table 4 . The majority of treatment-related toxicities included myelosuppression. Leukopenia, neutropenia and mucositis of Grade 3 or greater occurred in 36, 18 and 9% of the patients, respectively. No patients died during treatment. During and after treatment, no ischemic change or necrosis due to the effects of radiation and concurrent chemotherapy was found in the reconstructed organs.
DISCUSSION
Carcinoma of the cervical esophagus extends easily and frequently upward to the hypopharynx or downward to the thoracic esophagus, and most tumors are located at the border of the hypopharynx or the thoracic esophagus. However, carcinoma of the cervical esophagus is a disease distinct from carcinoma of the hypopharynx or thoracic esophagus. Larynx-preserving esophagectomy for carcinoma of the cervical esophagus can be performed safely and can lead to the long-term survival of selected patients (2, 3) . In the present study, even if patients had metastasis to the upper mediastinal lymph nodes, larynx-preserving cervical esophagectomy could be performed (Table 3 ). The selection of reconstructive procedure depends on the resected length of the esophagus necessary to ensure adequate distal esophageal margins, whether gastric pull-up adapts to total esophagectomy and whether free jejunal transfer accommodates the cervical esophagectomy with or without pharyngolaryngectomy. Kakegawa et al. (4) have reported that the incidence of metastasis to the upper mediastinal lymph nodes (11.4%) is similar to that to the cervical paratracheal lymph nodes (14.3%) and deep cervical lymph nodes (14.3%). In the present study, the incidence of metastasis to the upper mediastinal lymph nodes was 38% ( Table 1 ). The lymphatic drainage of the cervical esophagus is primarily to the paratracheal lymph nodes; therefore, carcinoma of the cervical esophagus spreads easily and frequently upward to the cervical lymph nodes or downward to the upper mediastinal lymph nodes or both. For this reason, we routinely perform dissection of the upper mediastinal lymph nodes as well as that of the bilateral cervical paratracheal and the deep cervical lymph nodes.
The reported 3-and 5-year survival rates for cervical esophageal carcinoma treated with surgical resection range from 18 to 35.4% and from 12 to 42%, respectively (2,5 -8) . The prognosis of patients with cervical esophageal cancer is worse than that of patients with hypopharyngeal cancer (7, 8) . Factors previously reported to influence the long-term survival of patients include both carcinoma of the cervical esophagus and carcinoma of the hypopharynx. Therefore, we reported prognostic factors affecting survival in our previous study, including carcinoma of the cervical esophagus (excluding hypopharyngeal cancer). In our previous study, prognostic factors affecting survival after surgical resection were sex, high T factor, lymph node involvement, palpable cervical lymph nodes, vocal cord paralysis, lymphatic invasion and extracapsular invasion (2) . In particular, the 3-year survival rate in patients with metastasis to mediastinal lymph nodes (M1 lymph/Stage IV) was 0% (2). Therefore, we believe that carcinoma of the cervical esophagus requires multimodal treatment, such as post-operative radiotherapy with concurrent chemotherapy.
Cooper et al. (9) Single-modality treatment after surgical resection cannot guarantee long-term survival; therefore, multimodal therapy, such as post-operative chemotherapy and radiotherapy, is essential for the treatment of cervical esophageal carcinoma. However, we are concerned about the adverse effects of post-operative chemoradiotherapy upon the reconstructed organs, especially free jejunal grafts, and the patient's general condition after the operation. Single-and multiinstitutional randomized studies and retrospective studies have shown that the concurrent chemotherapy regimen modified by reducing the platinum dose, increasing its frequency and adding a complementary chemotherapeutic agent remains well tolerated and is more effective than radiotherapy alone (10) (11) (12) .
On the basis of the results of our previous study and these studies of post-operative adjuvant or definitive radiotherapy with concurrent chemotherapy for locally advanced carcinoma of the head and neck, we performed a pilot study and retrospectively assessed the toxic effects and efficacy of post-operative radiotherapy with concurrent low-dose cisplatin chemotherapy in selected patients with metastasis to the upper mediastinal lymph nodes (M1 lymph/Stage IV), a factor indicating an extremely poor prognosis. Nine patients (82%) completed post-operative radiotherapy and two or more cycles of concurrent chemotherapy with cisplatin. The majority of treatment toxicities included myelosuppression. Leukopenia, neutropenia and mucositis of Grade 3 or greater occurred in 36, 18 and 9% of the patients, respectively. However, during the protocol treatment, no Grade 4 treatment-related toxicity occurred and no patients died. A low dose of cisplatin decreases the likelihood of adverse effects and death related to post-operative treatment with the combination of radiotherapy and concurrent chemotherapy with cisplatin (1). During and after treatment, no reconstructed organs underwent ischemic change or necrosis due to the effects of radiation and concurrent chemotherapy. The combination of post-operative radiation and concurrent chemotherapy with low-dose cisplatin is a well-tolerated treatment with mild-to-moderate adverse effects which causes no damage to reconstructed organs.
With a median follow-up period of 39.5 months (range, 16 -64 months), the median survival time was 33 months. The 1-and 3-year overall survival rates were 90 and 67%, respectively (Fig. 2) . Tumors recurred in four patients (36%). The pattern of recurrence was more often distant metastasis (75%) than locoregional spread (0%). In our previous study, the 3-year survival rate was 0% in patients with metastasis to mediastinal lymph nodes (M1 lymph/Stage IV), and the pattern of recurrence after operation was more often locoregional spread (82%) than distant metastasis. Triboulet et al. (7) have reported that post-operative radiotherapy for carcinoma of the hypopharynx and cervical esophagus improves survival and achieves a 3-year survival rate of 35%. However, large randomized, controlled studies have demonstrated that the combination of post-operative radiotherapy with concurrent chemotherapy is superior to post-operative radiation alone (1) . The combination of post-operative radiation and concurrent chemotherapy with low-dose cisplatin improves the rates of locoregional control and overall survival in patients with locally advanced squamous cell carcinoma of the cervical esophagus. We advocate that the indications for the combination of post-operative radiation with concurrent chemotherapy be expanded to include patients with a high T factor and lymphatic invasion, as this treatment is well tolerated, is associated with mild-to-moderate adverse effects and improves survival rates.
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CONCLUSION
The combination of post-operative radiation and concurrent chemotherapy with low-dose cisplatin is well tolerated, is associated with mild-to-moderate adverse effects and has the potential to improve the rates of locoregional control and overall survival in patients with locally advanced squamous cell carcinoma of the esophagus. Therefore, we advocate that the indications for this treatment be expanded to include patients with a high T factor and lymphatic invasion.
